Publication | Closed Access

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

Hematological MalignancyTumor BiologyImatinib Treatment DifferMedicineHematologyPathologyAdult T-cell Leukemia-lymphomaOncologyRadiation OncologyCancer ResearchHealth Sciences